Clinical Trial Update: The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial [Phase 3]

View source ↗

Summary

The Phase 3 HERO open-label extension trial for Prader-Willi syndrome-related hyperphagia has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Snippet

Sponsor: Aardvark Therapeutics, Inc. | Conditions: Hyperphagia, Prader-Willi Syndrome | Phase 3 | Status: SUSPENDED